IFP Advisors’s Werewolf Therapeutics HOWL Stock Holding History

IFP Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$1	–	4966
2025 Q1	$1	Hold	1	–	–	﹤0.01%	4290
2024 Q4	$1	Buy	+1	New	+$2	﹤0.01%	4587

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

IFP Advisors's HOWL Position: Q2 2025 in Review

IFP Advisors sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 1 share — an estimated $1 sold.

IFP Advisors first reported a position in HOWL in Q4 2024 and held it in 2 quarters. The position peaked at $1 in Q1 2025. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

IFP Advisors reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 1 Werewolf Therapeutics share in Q2 2025, an estimated $1.
IFP Advisors first reported a position in Werewolf Therapeutics in Q4 2024 and held it in 2 quarters.
IFP Advisors's Werewolf Therapeutics position peaked at $1 in Q1 2025.
65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.